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Suboptimal dietary zinc (Zn2+) intake is increasingly appreciated as an important public health issue. Zn2+ is an essential mineral,
and infants are particularly vulnerable to Zn2+ deficiency, as they require large amounts of Zn2+ for their normal growth and
development. Although term infants are born with an important hepatic Zn2+ storage, adequate Zn2+ nutrition of infants mostly
depends on breast milk or formula feeding, which contains an adequate amount of Zn2+ to meet the infants’ requirements. An
exclusively breast-fed 6months old infant suffering fromZn2+ deficiency caused by an autosomal dominant negativeG87Rmutation
in the Slc30a2 gene (encoding for the zinc transporter 2 (ZnT-2)) in the mother is reported. More than 20 zinc transporters
characterized up to date, classified into two families (Slc30a/ZnT and Slc39a/Zip), reflect the complexity and importance of
maintaining cellular Zn2+ homeostasis and dynamics. The role of ZnTs is to reduce intracellular Zn2+ by transporting it from
the cytoplasm into various intracellular organelles and by moving Zn2+ into extracellular space. Zips increase intracellular Zn2+ by
transporting it in the opposite direction. Thus the coordinated action of both is essential for the maintenance of Zn2+ homeostasis
in the cytoplasm, and accumulating evidence suggests that this is also true for the secretory pathway of growth hormone.
1. Introduction
Zinc (Zn2+) is an essential mineral, and infants are partic-
ularly vulnerable to Zn2+ deficiency as they require large
amounts of Zn2+ for their normal growth and development
[1–4]. Further, suboptimal dietary zinc intake is increasingly
appreciated as an important public health issue and has been
recently reviewed in a workshop organised by the World
Health Organization [5]. The rapid growth experienced by
term infants during the first months of life, while they
are exclusively breastfed, underscores the appropriateness
of breast milk. In particularly in the first three months,
Zn2+ occurs in breast milk unlike iron and copper at much
higher concentration [6]. Until recently it was not knownwhy
some otherwise healthy and normal nourished and nursing
mothers may present with low Zn2+ levels in breast milk
causing various abnormalities including growth arrest in
the baby. Transient neonatal zinc deficiency (TNZD; OMIM
number 608118) is one of the disorders well described [7–
11] which is characterized by a low level of Zn2+ found in
serum of exclusively breast-fed infants which occurs due
to the defective secretion of Zn2+ into mothers milk. This
disorder is well distinct, clinically as well as genetically,
from the other Zn2+-related entity specified as acrodermatitis
enterohepathica (AEZ; OMIM number 201100), where the
uptake of Zn2+ is the inborn error of metabolism [12–14].
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Here we describe the clinical case of an exclusively breast-
fed 6 months old infant presented to our outpatient clinic
suffering from Zn2+ deficiency caused by an autosomal
dominant negative G87R mutation in the zinc transporter
ZnT2 gene (SLC30A2) in the mother. In addition, as the
mechanism of Zn2+ on growth and development is not well
known, we focus further on its impact on growth hormone
production/secretion.
2. Case Report/Methods
2.1. Case Report. Following an uneventful pregnancy the
baby girl (II.3) was born at term (birth weight 3210 g, 50th
centile; birth length 49 cm, 50th centile) [15] (Figure 1). The
mother is of Philippine origin and the father of Swiss origin.
The family history is uneventful and no genetic diseases are
reported. The postnatal adaptation was normal. However,
at the age of 6 months the infant was presented to the
outpatient clinic of dermatology in the University of Bern,
Switzerland. The clinical examination revealed an otherwise
healthy, exclusively breast-fed 6 months old infant presented
with a 3weeks history of increasing skin problems, abdominal
cramps, and diarrhoea with no obvious malnutrition. The
skin lesions involving the face in a perioral distribution
(Figure 2(a)), head (Figure 2(b)), and in the anal area
(Figure 2(c)) appeared like an acrodermatitis enteropathica
while the analysis of serum revealed a significantly low Zn2+
level (Table 1) and decreased level of alkaline phosphatase.
Serum Zn2+ level in the mother was measured normal, while
Zn2+ concentration in mother’s breast milk was 0.12mg/kg,
which was significantly lower than the normative values
(Table 1). Hence, all the clinical parameters were in line
with the diagnosis of TNZD. In addition, while analysing
length, weight, and length velocity of the infant, a stunted
growth (IGF-I and IGF-BP3 levels at −2.3 SDS, −2.9 SDS,
resp.) and a failure to thrive became obvious starting at the
age of 3 months and progressed further until the age of 6
months, at the time when Zn2+ supplementation was started
(Figure 3). At that point the infant also presented with a
length that significantly dropped below the 3rd centile on
the growth curve (Figure 3). An oral Zn2+ supplementation
therapy (administered p.o, 4mg/kg/day, as zinc sulphate
heptahydrate) initiated and thereafter led to disappearance of
all the clinical symptoms within the next four weeks.
2.2. DNA Isolation. For the genetic studies, written informed
consent was obtained from both parents. Genomic DNA was
isolated from peripheral leukocytes of the affected subjects
using the QIAamp blood extraction kit (Qiagen AG, Basel,
Switzerland) and used as a template for analysis of the ZnT2
gene. The concentration of each sample was determined by
measuring the optical density of the purified DNA at 260 and
280 nm.
2.3. Amplification and Sequencing of Genomic DNA. The
genomic organization of human ZnT2 was determined from
published internet data (http://www.ncbi.nlm.nih.gov/), and
(I) 1
(II) 1/2/3
Figure 1: Pedigree. Full half circle: heterozygosity G87R SLC30A2;
hatched circle: clinical signs during infancywhile breastfed. II.1, II.2,
and II.3 were breastfed for 3, 1, and 6 months, respectively. II.3 is
reported and described.
each one of the 8 coding exons was amplified by PCR ampli-
fication using established primers [10]. For PCR, approx-
imately 100 ng of genomic DNA was used as template in
a PCR SuperMix High Fidelity (Invitrogen, UK) in a total
reaction volume of 50 𝜇L. PCR was carried out in TGradient
Thermoblock (Biometra, Germany) under the following con-
ditions: 33 cycles with an initial denaturation step at 94∘C for
2min, thereafter 94∘C for 45 s, annealing at 60∘C (for exons
1), 55∘C (for exon 2 and 4), 61∘C (for exon 3), 59∘C (for exon 5,
6, 7), 57∘C (for exons 8) for 45 s, andwith an extension of 72∘C
for 1min. Amplification was completed with an additional
extension step at 72∘C for 5min. Negative controls included
no template control. PCR products were separated on 1.5%
agarose gel and stained with ethidium bromide. The bands
corresponding to each specific PCR product were purified
with QIAquick PCR Purification Kit (Qiagen AG, Basel,
Switzerland) and sequenced on an ABI 373 automated DNA
sequencing system (Applied Biosystems).The sequenceswere
confirmed by re-PCR and resequencing from the genomic
DNA of both strands.
3. Results
3.1. Identification of a Heterozygous G87R ZnT-2 Mutation.
We identified a heterozygous G87R ZnT2 mutation in the
mother (I.1) as well as in the baby/girl (II.3) (Figures 1–4).
To know that II.3 does carry the mutation is very much of
importance for her possible life as a breastfeeding mother.
This mutation has been previously reported and studied in
most detail at the functional level [10]. In this study as well
in a previous report the authors showed that a functional
inactivation of the ZnT2 is the underlying cause of TNZD
[10, 11].
3.2. Impairment of Growth and Development. The aim of our
study, however, was to focus on the impact of length and
length velocity in a Zn2+-deficient environment. Although
the mechanisms are not well studied, it is well known and
accepted that prolonged Zn2+ deficiency during infancy as
well as childhood is not a negligible cause for stunting growth
and failure to thrive [1–5].
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Figure 2: Skin lesions. Skin lesions in a perioral region (a), on the head (b), and in the anal region (c).
3.3. Effect of Zn2+ Supplementation on Growth. As demon-
strated in Figure 3, the oral Zn2+ supplementation therapy
(administered p.o, 4mg/kg/day, as zinc sulphate heptahy-
drate) resulted after 4 months in a complete catch-up growth
of the child as well as normalized the IGF-I and IGF-BP3 lev-
els (Table 1).Therefore, a sufficient Zn2+ serum concentration
in this infant seems also to be of crucial importance for GH
secretion and, thus, normal growth and development.
3.4. Zn2+ Transporters and GH Secretion. By Inoue et al.,
ZnT5-null mice, as the result of crossing between het-
erozygous mice according to Mendelian expectations, were
cloned and provided some in vivo data about the phenotype
caused by the complete deletion of only one zinc transporter,
namely, ZnT5 [16]. ZnT5-null mice displayed abnormal bone
development, loss of weight, and lethal, male-specific, car-
diac arrhythmia. Interestingly, these mice presented with
significantly impaired growth when compared to the wild-
type animals and with a high degree of osteopenia due to
systemic decrease in bone density as the results of the reduced
activity of osteoblasts [16]. Although the authors did not
focus on growth, it has been nicely described and depicted
in this study [16]. Further, Robinson et al. used the advantage
of enhanced green fluorescent protein (eGFP), which when
expressed from cell-specific promoters in transgenic animals,
allows identification of specific cell types in situ and provides
a fluorescent tag for their isolation and analysis, using
fluorescence-activated cell sorting (FACS) technique [17, 18].
Therefore, eGFP was targeted to the secretory granules of
pituitary GH-producing cells in transgenic mice (GH-eGFP
transgenic mouse) [18, 19], followed by the FACS sorting of
somatotrope cells (eGFP+ cells). Analysis of specific gene
expression patterns using microarray technique was per-
formed, and relative expression data of all zinc transporters
assessed (Table 2) revealed the expression of ZnT5 to be the
strongest in somatotropes. Hence, these data suggest high
involvement of ZnT5 in the processes of GH storage and
secretion.
4. Discussion
4.1. Zn2+ Deficiency. The initial main symptoms of mild
Zn2+ deficiency are growth faltering as well as anorexia.
Further prolonged and/or severe zinc deficiency presents
with dermatitis and alopecia and is often expressed in growth
impairment as well as neuropsychological alterations [20].
Infants are particularly vulnerable to Zn2+ deficiency, as
they require large amounts of Zn2+ for their normal growth
and development. Although term infants are born with an
important hepatic zinc storage, adequate zinc nutrition of
infants mostly depends on breast milk (especially in the
first 3 months of lactation) or milk formula feeding, which
contains an adequate amount of Zn2+ to meet the infants’
requirements [6]. However, there are several causes for
Zn2+ deficiency during infancy. First, it may be a result
of deficient nutrition due to low level of Zn2+ in the
breast milk or to consumption of food that is poor in
Zn2+ bioavailability, or second, it is associated with distinct
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Table 1: Laboratory data of the child (II.3) and mother.
Child
MotherBefore Zn2+
supplementation
After 1 month on Zn2+
supplementation Normative values
Zn2+ in serum (𝜇mol/L) 2.3 14.6 9–21 12.2 (11–18)
Alkaline phosphatase (IU/L) 73 465 96–336 88 (36–108)
IGF-I (ng/mL) 10 (−2.3 SDS) 62 (0 SDS) 18–146
IGF-BP3 (mg/L) 0.89 (−2.9 SDS) 2.95 (+0.5 SDS) 1.19–3.81
Zn2+ in breast milk (mg/kg) 0.12mg/kg (0.2–0.76(6))
Table 2: Relative expression data of zinc transporters in GFP-sorted somatotrope cells from GH-eGFP transgenic mouse.
Zn transporter Relative expression Gene bank Significance
Slc30a1 1.7235773 NM 009579 0.76
Slc30a3 2.1382113 U76007 0.66
Slc30a4 7.08943 NM 011774 0.18
Slc30a5 28.886179 NM 022885 0.028
Slc30a6 4.1382113 AF233346 0.34
Slc30a7 9.601625 AF233322 0.12
Slc30a9 9.593495 BB117951 0.12
𝑃 < 0.05 is significant.
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Figure 3: Growth chart of the patient. The solid circles indicate the
length measurements. Percentiles are shown on extreme right. The
arrows pointing up and down indicate the beginning and the end of
the Zn2+ supplementation therapy.
genetic disorders in Zn2+ metabolism [10, 11, 13, 21]. One
of those genetic defects is associated with mutations of
the intestinal Zn2+-specific transporter Slc39a4/Zip4 [12, 13],
which is responsible for Zn2+ absorption in the small intestine
and when mutated leads to a rare, autosomal recessive
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Figure 4:Heterozygous G87Rmutation in the ZnT2 (SLC30A2) gene.
At position 87 of theZnT2 (SLC30A2) gene, a heterozygousmutation
G > C (Gly > Arg) is depicted.
disease called acrodermatitis enteropathica (AEZ) (OMIM
number 201100). AEZ manifests in impaired intestinal Zn2+
absorption; hence, patients harbouring AEZ require lifelong
zinc supplementation [14, 22]. Without therapy, plasma Zn2+
concentration and serum alkaline phosphatase, as well as
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urinary excretion of Zn2+, are very low [23]. Another genetic
defect is associated with a mutation within Slc30a4/ZnT4
and causes a reduced Zn2+ incorporation into mother’s
milk [11, 21]. Mice homozygous for a ZnT4 mutation are
known as lethal milk mice (lm−/lm− mouse) producing
milk, which is Zn2+ deficient (OMIM number 602095) [24].
As this phenotype in mice mirrors TNZD (OMIM number
608118) in breast-fed infants [7–9] Michalczyk et al. investi-
gated whether changes in the ZnT4 gene are responsible for
reducedZn2+ in breastmilk in human in two unrelatedmoth-
ers with low Zn2+ milk levels whose babies had developed
Zn2+ deficiency. Their findings suggested that the lm−/lm−
mouse is not the corresponding model for the human Zn2+
deficiency condition [25]. Finally, TNZD in humans was
found to be associated with mutations in SLC30A2/ZnT2.
Gene knockdown of ZnT2 in mammary epithelial cells
reduced Zn2+ secretion, suggesting a role for this transporter
in Zn2+ secretion from this cell type [11]. ZnT2 was also
found to be upregulated and relocalised to vesicles after
exposure of mammary epithelial cells to prolactin. Similarly,
mammary gland ZnT2 was upregulated and relocalised to
the luminal membrane in lactating rats when plasma zinc
increased during lactation [26, 27]. Heterozygous H54R
and G87R mutations in ZnT2 were recently identified in
women presenting with a Zn2+-deficient milk [10, 11]. As
there is no impairment in Zn2+ uptake in the gut in affected
babies, their infants, consequently, developed TNZD that
was resolved after oral Zn2+ supplementation [10, 11]. As
previously reported by Lasry et al. [10] we identified and char-
acterized a heterozygous G87R mutation in ZnT2 leading to
production of Zn2+-deficient milk in a mother originated
from the Philippines; as a result, their exclusively breast-fed
infants developed TNZD with low Zn2+ blood levels that
resolved upon Zn2+ supplementation. As far as the function
is concerned, Lasry et al. showed that the G87R mutation is
a loss of function mutation and they provided, therefore, the
first evidence for the dominant inheritance of heterozygous
ZnT2 mutations via negative dominance due to homodimer
formation [10].
4.2. Impact of Zn2+ on Growth Hormone Secretion [28]. The
growth hormone-1 (GH-1) gene is mainly expressed as amajor
22 kDa isoform in somatotrope cells of the anterior pituitary
gland. After being translated, GH protein passes throughout
the regulated secretory pathway where it gets packed and
stored in concentrated forms in secretory granules enabling
a regulated release in circulation upon GHRH stimulation
[29, 30].
Zn2+ is considered as the second most abundant “trace”
metal in the human body which is required for numerous
cellular mechanisms like DNA synthesis, protein synthesis,
cell growth, and division [31] as well as for many phys-
iological processes like immune function [32] and repro-
duction [33, 34]. Hence, cellular Zn2+ homeostasis and
dynamics are tightly regulated and maintained by various
Zn2+ transporters responsible for transporting these high
charge density ions across cellular membranes and various
intracellular organelles [35, 36]. Over two decades ago, a high
concentration of Zn2+ was reported to be localized mostly
in the Golgi complex and GH-containing secretory granules
of rat anterior pituitary cells [37], suggesting in that way, an
important role of Zn2+ in the regulated secretory pathway of
GH. During the process of secretory granule biogenesis, self-
association (aggregation) of a hormone destined for secretion
facilitates its storage in granules in fairly high amounts, and
in the case of GH, it occurs in the presence of Zn2+ [38].
4.3. The Biogenesis of GH Secretory Granules Begins with
Zn2+-Mediated GH Aggregation at Acidic pH in the Trans-
Golgi Lumen. The complex process of secretory granule
biogenesis begins with aggregation of proteins (hormones)
destined for secretion to form dense cores of granules
composed of large insoluble aggregates. Upon appropriate
stimulation, aggregates are released into the bloodstream
leading to a burst of hormone on a time scale much faster
than it could be achieved from increased synthesis.
Protein aggregation takes place in the lumen of trans-
Golgi layer where specific environmental factors seem to play
an important role in inducing this process. In fact, apart
from specific pH requirements [39, 40], aggregation of GH
apparently requires high amounts of divalent cations like
Zn2+ [37].
A step further towards unravelling the role of Zn2+ in
storage of GH in secretory granules came with the study
reporting that two Zn2+ associates per GH dimer in a
cooperative fashion through binding at high-affinity residues
in GH (His18, His21, and Glu174) [41]. Replacement of these
residues with alanine caused reductions of dimeric GH for-
mation as demonstrated by size-exclusion chromatography
and sedimentation equilibrium analysis. In addition, the
data presented also demonstrate that Zn2+ binding to GH
would enhance stability of the stored form and that Zn2+-GH
complex was more stable to denaturation when compared to
monomeric GH ultimately proposing that Zn2+-GH dimer
may be the main storage form in the secretory granules [41].
The potential contribution of high-affinity Zn2+-binding
residues in GH to the pathogenic mechanisms involved
in dominantly transmitted isolated GH deficiency type II
(IGHD II) was further studied by Iliev et al. [42]. The
production and extracellular secretion ofwt-hGH transiently
transfected in GH
4
C
1
cells (rat pituitary tumour cells) were
compared to that of GH mutants in which the amino acids
that bind Zn2+ with high affinity were mutated to alanine
in various combinations. When wt-hGH was coexpressed
with any of the Zn2+-binding GH mutants, constitutive
GH secretion (i.e., without stimulation) and intracellular
production remained unaffected. Interestingly, each of the
Zn2+-binding GHmutants (single, double, or triple mutants)
singly expressed displayed about 50% lower extracellular
secretion and intracellular production when compared to the
wt-hGH suggesting possible role of these residues in GH
stability.
GH and PRL are two hormones that are structurally
related, and therefore it is of no surprise that they display
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many similarities in the process of aggregation as reported
in the study mentioned above. However, alanine mutation
introduced at His27 in hPRL (topologically corresponding to
His18 in hGH) resulted in H27A-PRLmutant reported not to
bind Zn2+ [43]. Interestingly, even without the high-affinity
Zn2+ binding site, H27A-PRL is still able to aggregate in the
presence of Zn2+ with parameters similar to aggregation of
wt-PRL [40]. Hence, these data suggest that PRL and GH
do not behave similarly in the presence of Zn2+ and that
PRL does not form dimer under the conditions that GH
does, indicating that the dimer is unlikely to be the storage
form of PRL in secretory granules. Zn2+ binding to human
PRL and GH can occur through histidine residues (the high-
affinity binding sites) [41, 43] or through glutamate, aspartate,
and glutamine residues (the low-affinity binding sites) [44].
Acidic pH in the trans-Golgi lumen where the process of
aggregation occurs leads to protonation of His residues
preventing their binding to Zn2+. Therefore, it is more likely
that Zn2+ binding to glutamate and aspartate residues (low-
affinity binding) of PRL facilitates the formation of PRL
oligomers as the storage form in dense cores of secretory
granules.
Finally, asmentioned earlier Zn2+ binding toGH through
high-affinity binding sites is proven to be necessary for
the formation of GH dimers, but whether this is the final
storage form of GH in secretory granules still remains to
be elucidated. Alternatively, additional intramolecular cross-
linking might occur through low-affinity Zn2+-binding with
amino acids other than histidine (as described above for
PRL) enhancing in that way GH aggregation and storage in
secretory granules.
4.4. Zinc Transporters Mediate Zn2+ Dynamics in the Early
Secretory Pathway and Might Play an Important Role in the
Formation of GH-Containing Secretory Granules. Out of all
proteins synthesized in eukaryotic cells approximately one-
third is targeted to the secretory pathway [45] and the first
compartment encountered along their road towards secretion
is the ER. Together with Golgi complex, ER comprises the
early secretory pathway, which plays the key role in regulating
the folding, assembly, and transport of newly synthesized
proteins and modification and trafficking during the secre-
tory process. There are estimates that between three and ten
percent of all proteins in mammalian genomes bind Zn2+
[46], and many zinc-dependent proteins pass through the
secretory pathway on theirway to other compartmentswithin
the cell (e.g., vacuole, lysosomes) or prior to their secretion.
Due to its high charge density, Zn2+ requires transporters
to move it across the cellular membranes and in and out of
each of the organelles participating in the regulated secretory
pathway (ER, Golgi complex, and secretory granules). More
than 20 zinc transporters identified and characterized up to
date, classified into two families (Slc30a/ZnT and Slc39a/Zip),
reflect the complexity and importance ofmaintaining cellular
Zn2+ homeostasis and dynamics.The role of ZnTs is to reduce
intracellular Zn2+ by transporting it from the cytoplasm
into various intracellular organelles and by moving Zn2+
into extracellular space. Zips increase intracellular Zn2+ by
transporting it in the opposite direction. Thus the coordi-
nated action of both is essential for the maintenance of Zn2+
homeostasis in the cytoplasm, and accumulating evidence
suggests that this is also true for the secretory pathway.
4.5. Conclusion: Where the Mother’s Milk Meets the Baby’s
Growth. Having discussed the importance of Zn2+ as well as
their individual intracellular transporters it comes without
any surprise that an adequate Zn2+ concentration in the
child’s plasma is of high importance for normal growth and
development [1, 3, 28, 47–49].
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